证券代码：600594 证券简称：益佰制药 公告编号:2025-010 贵州益佰制药股份有限公司 第八届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 1、贵州益佰制药股份有限公司（以下简称"公司"）第八届董事会第十一 次会议通知于 2025 年 4 月 11 日以电子邮件等方式送达全体董事、监事及高管。 本次会议于 2025 年 4 月 24 日在公司行政楼会议室以现场加通讯会议方式召开。 2、本次会议应出席董事 6 人，实际出席董事 6 人，其中董事长窦啟玲女士， 副董事长窦雅琪女士以通讯方式参加。本次会议由董事长窦啟玲女士召集和主 持。 3、公司全体监事及高管列席了会议。 4、本次会议的召集和召开符合《公司法》及《公司章程》等相关规定。 二、董事会会议审议情况 本次会议以记名投票表决方式通过了如下议案： 1、会议以 6 票同意，0 票弃权，0 票反对，审议通过了《公司 2024 年年度 总经理工作报告》； 2、会议以 6 票同意，0 票弃权，0 票反对，审议通过了《公司 ...

证券代码：600594 证券简称：益佰制药 公告编号：2025-012 贵州益佰制药股份有限公司 关于 2024 年年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 贵州益佰制药股份有限公司（以下简称"公司"）2024 年年度拟不进行利 润分配，亦不进行资本公积金转增股本和其他形式的分配。 公司 2024 年年度利润分配预案已经公司第八届董事会第十一次会议、第 八届监事会第九次会议审议通过，尚需提交公司 2024 年年度股东大会审议。 本次利润分配方案不触及可能被实施其他风险警示的情形。 一、利润分配预案内容 经中证天通会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 公司母公司报表中期末未分配利润为人民币-280,535,603.78 元。2024 年年度公 司实现归属于上市公司股东的净利润为人民币-317,215,358.07 元。 根据《公司法》《公司章程》等相关规定，综合考虑行业发展情况、公司现 阶段经营业绩情况、生产经营需要及未来资金投入的需求等因素后，公 ...

贵州益佰制药股份有限公司 营业收入扣除情况表 专项核查报告 目 录 中证天通会计师事务所 （特殊普通合伙） 中国·北京 海淀区西直门北大街 43 号 金运大厦 B 座 13 层 邮编 100044 电话 010 6221 2990 传真 010 6225 4941 网址 www.zzttcpa.com 贵州益佰制药股份有限公司 营业收入扣除情况表专项核查报告 中证天通(2025)证审字 21100027-2 号 贵州益佰制药股份有限公司全体股东： | 专项核查报告 | | 1-2 | | --- | --- | --- | | 公司 2024 | 年度营业收入扣除情况表及说明 | 1-3 | 中证天通会计师事务所（特殊普通合伙） 我们接受委托，在审计了贵州益佰制药股份有限公司（以下简称"益佰制药公司"） 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并 及母公司现金流量表、合并及母公司股东权益变动表以及财务报表附注的基础上，对 后附的《益佰制药公司 2024 年度营业收入扣除情况表及说明》（以下简称"营业收入扣 除情况表"）进行了专项核查。 按照《上海证券交易 ...

上期非标事项在本期消除 的专项说明 关于贵州益佰制药股份有限公司 2024 年度 上期非标事项在本期消除的专项说明 1-3 中证天通会计师事务所（特殊普通合伙） 中证天通会计师事务所 （特殊普通合伙） 中国·北京 海淀区西直门北大街 43 号 金运大厦 B 座 13 层 邮编 100044 电话 010 6221 2990 传真 010 6225 4941 网址 www.zzttcpa.com 关于贵州益佰制药股份有限公司 2023 年度带强调事项段的无保留审计意见 目 录 内部制控审计报告的专项说明 中证天通(2025)证专审 21100010-1号 贵州益佰制药股份有限公司全体股东： 我们接受委托，审计了贵州益佰制药股份有限公司（以下简称益佰制药 公司）2024 年 12 月 31 日的财务报告内部控制的有效性，并于 2025 年 4 月 24 日出具了标准无保留意见的内部控制审计报告（中证天通(2025) 证专审 21100010号）。我们的审计是按照《企业内部控制审计指引》及中国注册会 计师执业准则的相关要求进行的。 根据中国证券监督管理委员会《监管规则适用指引——审计类第 1 号》 的相关要求，我们 ...

贵州益佰制药股份有限公司 2024 年度 内部控制审计报告 目 录 内部控制审计报告 1-3 中证天通会计师事务所（特殊普通合伙） - 1 - 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性 发表审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 中证天通会计师事务所 （特殊普通合伙） 中国·北京 海淀区西直门北大街 43 号 金运大厦 B 座 13 层 邮编 100044 电话 010 6221 2990 传真 010 6225 4941 网址 www.zzttcpa.com 内部控制审计报告 中证天通(2025)证专审 21100010号 贵州益佰制药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要 求，我们审计了贵州益佰制药股份有限公司（以下简称益佰制药公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效 性是益佰制药公司董事会的责任。 二、注册会计师的责任 内部控制具有固 ...

贵州益佰制药股份有限公司 2024 年度 财务报表之审计报告 目 录 | 一、审计报告 | 1-5 | | --- | --- | | 二、已审公司财务报表 | | | 1.合并资产负债表 | 1-2 | | 2.母公司资产负债表 | 3-4 | | 3.合并利润表 | 5 | | 4.母公司利润表 | 6 | | 5.合并现金流量表 | 7 | | 6.母公司现金流量表 | 8 | | 7.合并所有者（股东）权益变动表 | 9-10 | | 8.母公司所有者（股东）权益变动表 | 11-12 | | 9.财务报表附注 | 13-96 | 中证天通会计师事务所（特殊普通合伙） 中证天通会计师事务所 （特殊普通合伙） 中国·北京 海淀区西直门北大街 43 号 金运大厦 B 座 13 层 邮编 100044 电话 010 6221 2990 传真 010 6225 4941 网址 www.zzttcpa.com 审计报告 中证天通(2025)证审字 21100027号 贵州益佰制药股份有限公司全体股东： 一、审计意见 我们审计了贵州益佰制药股份有限公司（以下简称益佰制药公司）财务报表，包括 2024 年 12 月 ...

关于贵州益佰制药股份有限公司 非经营性资金占用及其他关联资金往来情况 目 录 1、 专项审计报告 汇总表的专项审计报告 2、 附表 委托单位：贵州益佰制药股份有限公司 审计单位：中证天通会计师事务所（特殊普通合伙） 联系电话：010 6221 2990 关于贵州益佰制药股份有限公司 非经营性资金占用及其他 关联资金往来的专项说明 目 录 | 关于贵州益佰制药股份有限公司非经营性资 | 1-2 | | --- | --- | | 金占用及其他关联资金往来的专项说明 | | | 贵州益佰制药股份有限公司 2024 年度非经营 | | | 性资金占用及其他关联资金往来情况汇总表 | 1-2 | 贵州益佰制药股份有限公司全体股东: 我们接受贵州益佰制药股份有限公司(以下简称"益佰制药公司")委托, 根据中国注册会计师执业准则审计了益佰制药公司 2024年 12月 31日的合并 及母公司资产负债表,2024年度合并及母公司利润表、合并及母公司现金流 量表、合并及母公司股东权益变动表和财务报表附注,并出具了中证天通 (2025)证审字 21100027号无保留意见审计报告。 根据《上市公司监管指引第 8号-- 上市公司资 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0120 | -0.0860 | 86.05 | 0.0560 | | 每股净资产（元） | 3.13 | 3.56 | -12.08 | 3.9 | | 每股公积金(元) | 0.83 | 0.83 | 0 | 0.93 | | 每股未分配利润(元) | 0.94 | 1.33 | -29.32 | 1.60 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 5.01 | 5.73 | -12.57 | 6.84 | | 净利润(亿元) | -0.09 | -0.68 | 86.76 | 0.44 | | 净资产收益率(%) | -0.38 | -2.26 | 83.19 | 1.44 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 25915.61万股，累计占流通股比： 32. ...

Financial Performance - The company reported a net profit attributable to shareholders of RMB -317,215,358.07 for the year 2024[7]. - As of December 31, 2024, the company's undistributed profits amounted to RMB -280,535,603.78[7]. - The company's operating revenue for 2024 was approximately ¥2.17 billion, a decrease of 22.92% compared to ¥2.82 billion in 2023[23]. - The net profit attributable to shareholders for 2024 was approximately -¥317.22 million, representing a decline of 406.79% from a profit of ¥103.40 million in 2023[23]. - The adjusted net profit attributable to shareholders, excluding non-recurring gains and losses, was -¥323.17 million in 2024, down 579.10% from ¥67.45 million in 2023[23]. - The basic and diluted earnings per share for 2024 were both -¥0.402, a decrease of 406.87% from ¥0.131 in 2023[24]. - The weighted average return on equity for 2024 was -11.781%, a decrease of 15.33 percentage points from 3.549% in 2023[25]. - The net cash flow from operating activities for 2024 was approximately ¥86.87 million, down 76.99% from ¥377.61 million in 2023[23]. - The total assets at the end of 2024 were approximately ¥4.10 billion, a decrease of 10.82% from ¥4.60 billion at the end of 2023[23]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥2.49 billion, down 13.68% from ¥2.88 billion at the end of 2023[23]. Operational Highlights - The company has a standard unqualified audit report from Zhongzheng Tiantong Accounting Firm[5]. - The board of directors and supervisory board members confirmed the authenticity and completeness of the annual report[3]. - The company will focus on future development strategies despite uncertainties in forward-looking statements[8]. - The company reported a significant decline in quarterly net profit, with the fourth quarter showing a loss of approximately -¥148.06 million[27]. - Non-recurring gains and losses included government subsidies of approximately ¥26.98 million, which positively impacted the financial results[30]. - The pharmaceutical industrial segment contributed 77.44% of total revenue, while the medical services segment accounted for 21.46%[40]. - The company holds 152 product varieties and 194 drug production approval numbers, with 64 varieties included in the national medical insurance catalog[41]. - The company has a unique third-generation platinum compound, injection-grade lobaplatin, which is a new drug and included in the national medical insurance catalog[41]. - The healthcare segment includes the operation and management of one general hospital and two specialized hospitals, focusing on high-quality medical services[42]. Market and Industry Trends - The pharmaceutical industry is facing cost pressures due to raw material price fluctuations and strict regulatory requirements[37]. - The aging population in China is driving demand for chronic disease medications and rehabilitation services, creating opportunities for the pharmaceutical sector[38]. - The government is promoting innovation in the pharmaceutical industry through policies that support the development of innovative drugs and medical devices[39]. - The pharmaceutical industry in China is expected to maintain steady growth, driven by increasing healthcare demands and ongoing reforms in the medical system[53]. - The silver economy in China is currently valued at approximately CNY 7 trillion, projected to grow to CNY 30 trillion by 2035, representing 10% of GDP, which will drive demand for TCM[58]. - The implementation of centralized drug procurement in 2024 is expected to further compress the profit margins of generic drugs, compelling companies to optimize cost management[59]. - The success rate of medical insurance negotiations for innovative drugs has increased to 85%, creating policy incentives for leading pharmaceutical companies[59]. Research and Development - The company has strengthened its R&D capabilities, achieving registration approvals for 12 products, including Azacitidine and Pulaosaf injection, and completed 405 new product filings by December 31, 2024[45]. - The company is focusing on digital transformation, integrating AI technology into business processes to enhance operational efficiency and decision-making capabilities[46]. - The company is committed to enhancing its product line through various strategies, including independent R&D and partnerships, to meet unmet clinical needs[44]. - The company is focusing on diversifying its product offerings, with ongoing development of innovative drugs like YBR-8002 and improvements in existing formulations[48]. - The company has established a robust R&D center to support its transition towards a diversified pharmaceutical group, focusing on chemical drugs, traditional Chinese medicine, and biopharmaceuticals[141]. Governance and Compliance - The company has enhanced its governance mechanisms to protect investor rights and ensure compliance with legal regulations[49]. - The company has established effective management mechanisms to prevent the controlling shareholder and related parties from occupying company funds, ensuring the protection of company interests[193]. - The board of directors actively engages in decision-making and has established four specialized committees to enhance governance and oversight[194]. - The company issued 49 temporary announcements and 4 periodic reports during the reporting period, emphasizing its commitment to transparency and timely information disclosure[198]. Marketing and Sales Strategy - The company is exploring a combined sales model for its health products, leveraging both self-operated sales teams and e-commerce[43]. - The company is actively expanding its market presence by upgrading its marketing strategies and enhancing its sales team structure[45]. - The company aims to balance cost control and innovation through the new DRG/DIP payment model, promoting a win-win situation for patients, medical insurance, and healthcare institutions[82]. - The company is adapting its marketing structure to align with the ongoing national medical reform and centralized procurement trends[178]. Risks and Challenges - The company faces risks related to R&D, including high investment and potential failure in drug development, and plans to enhance R&D efficiency and collaboration on advantageous products[184]. - The company acknowledges quality control risks due to complex production processes and will strengthen quality management to ensure compliance with new regulations and standards[185]. - The company is aware of regulatory and market risks from healthcare policies and will adapt its strategies to mitigate impacts on production costs and profitability[186]. - The company recognizes the potential impact of macroeconomic fluctuations on demand for pharmaceutical products and will monitor economic conditions closely[187].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 501,480,776.32, representing a decrease of 12.43% compared to CNY 572,646,100.11 in the same period last year[5] - The net profit attributable to shareholders was a loss of CNY 9,385,719.46, an improvement from a loss of CNY 68,454,808.45 year-over-year[5] - The company's gross profit margin for Q1 2025 was approximately -2.36%, compared to -11.80% in Q1 2024[20] - Net profit for Q1 2025 was a loss of ¥11,427,837.53, compared to a loss of ¥71,411,782.78 in Q1 2024, indicating a significant improvement[21] Cash Flow - The net cash flow from operating activities decreased by 92.14%, amounting to CNY 7,526,352.13 compared to CNY 95,754,548.97 in the previous year[5] - Cash inflow from operating activities in Q1 2025 was ¥531,101,158.22, a decrease of 30.93% from ¥769,767,157.87 in Q1 2024[25] - Cash outflow from operating activities totaled $523,574,806.09, a decrease of 22.3% compared to $674,012,608.90 in the previous period[26] - Cash outflow from investing activities was $6,671,319.56, down 69.9% from $22,157,326.31 in the previous period[26] - Cash inflow from financing activities was $222,999,999.50, an increase of 50.5% from $148,000,000.00 in the previous period[26] - The ending balance of cash and cash equivalents was $455,074,557.37, down from $766,811,919.96, a decrease of 40.6%[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,994,902,808.73, down 2.56% from CNY 4,099,701,241.48 at the end of the previous year[6] - The company's current assets totaled RMB 1,685,288,665.38, down from RMB 1,750,026,094.89, indicating a decrease of about 3.71%[15] - Total liabilities decreased to RMB 1,400,220,344.81 from RMB 1,493,590,940.03, reflecting a decline of about 6.25%[16] - The company's non-current assets totaled RMB 2,309,614,143.35, down from RMB 2,349,675,146.59, indicating a decrease of about 1.70%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,054, with no preferred shareholders[10] - The total equity attributable to shareholders was ¥2,480,372,737.03, slightly down from ¥2,489,758,456.49[18] - The total equity remained stable at RMB 791,927,400.00, unchanged from the previous period[16] - The company has a share repurchase account holding 7,533,500 shares as of March 31, 2025[12] Cost Management - The company reported a significant reduction in costs and expenses, contributing to the improved net profit margin despite the overall revenue decline[8] - Total operating costs for Q1 2025 were ¥512,206,331.73, down 19.34% from ¥635,203,702.04 in Q1 2024[20] - Research and development expenses for Q1 2025 were ¥20,616,783.17, a decrease of 9.56% from ¥22,795,778.94 in Q1 2024[20] Strategic Focus - The company is focusing on cost management and operational efficiency to navigate the current market challenges and improve financial performance in the upcoming quarters[8]